{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:10Z","timestamp":1789117690596,"version":"build-2803163510"},"reference-count":76,"publisher":"IOP Publishing","issue":"4","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute","award":["R00CA263016"],"award-info":[{"award-number":["R00CA263016"]}]},{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"crossref","award":["SP0A242412"],"award-info":[{"award-number":["SP0A242412"]}],"id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Prog. Biomed. Eng."],"published-print":{"date-parts":[[2026,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pediatric solid tumors continue to pose a major therapeutic challenge, with survival gains lagging behind those achieved in pediatric hematologic malignancies. While traditional approaches have focused on dose escalation and intensification of systemic therapies to improve survival, this strategy is often limited by significant short- and long-term morbidity from intensive multimodal treatment. Because children have developing organs and decades of life ahead, therapeutic strategies must balance durable tumor control with preservation of neurodevelopment, organ function, and quality of life. Immunotherapy has generated significant interest as an alternative to dose escalation; however, clinical translation in pediatric solid tumors has been limited by antigen heterogeneity, tumor plasticity, immune-cold or immune-excluded phenotypes, and a profoundly immunosuppressive tumor microenvironment. Bioengineered cellular therapies, particularly chimeric antigen receptor (CAR) T cells and CAR-modified natural killer (CAR NK) cells, provide a modular platform to address these barriers through synthetic receptor design, multi-antigen targeting, controlled activation, and improved trafficking to anatomically restricted sites such as the brain. However, engineering advances alone are unlikely to achieve durable benefit without parallel integration of quantitative\n                    <jats:italic>in vivo<\/jats:italic>\n                    monitoring capable of reporting biodistribution, persistence, and functional engagement. Non-invasive imaging and measurement-enabled approaches can provide mechanistic insight into therapeutic performance, discriminate between delivery failure and functional dysfunction, and support rational iteration of construct design, dosing, and route of administration. In this perspective, we review the current status of CAR T and CAR NK therapies in pediatric solid malignancies, outline key biological and engineering challenges, and propose a pediatric-centered development framework that integrates controllable cell engineering with quantitative, non-invasive assessment of\n                    <jats:italic>in vivo<\/jats:italic>\n                    behavior. By embedding measurement into the therapeutic design loop and prioritizing long-term safety and developmental outcomes alongside efficacy, next-generation engineered cell therapies may evolve toward adaptable, precision-guided systems capable of improving both survival and quality of life for children.\n                  <\/jats:p>","DOI":"10.1088\/2516-1091\/aea045","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:53:41Z","timestamp":1787957621000},"page":"043001","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach"],"prefix":"10.1088","volume":"8","author":[{"given":"Ana M","family":"Sandoval-Castellanos","sequence":"first","affiliation":[{"name":"University of California Davis"},{"name":"School of Medicine, University of California Davis"},{"name":"University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Rim","family":"Ahn","sequence":"additional","affiliation":[{"name":"University of California Davis"},{"name":"School of Medicine, University of California Davis"},{"name":"Center for Bioengineering in Medicine, School of Medicine, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-5418","authenticated-orcid":false,"given":"Robert J","family":"Canter","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-1850","authenticated-orcid":false,"given":"Erin G","family":"Brown","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California Davis"},{"name":"Center for Bioengineering in Medicine, School of Medicine, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-0655","authenticated-orcid":true,"given":"Jinhwan","family":"Kim","sequence":"additional","affiliation":[{"name":"University of California Davis"},{"name":"School of Medicine, University of California Davis"},{"name":"Center for Bioengineering in Medicine, School of Medicine, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"prgbaea045bib1","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1002\/cncr.33080","type":"journal-article","article-title":"Pediatric cancer mortality and survival in the United States, 2001\u20132016","volume":"126","author":"Siegel","year":"2020","journal-title":"Cancer"},{"key":"prgbaea045bib2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1235947","type":"journal-article","article-title":"Pediatric oncology drug development and dosage optimization","volume":"13","author":"Cheung","year":"2024","journal-title":"Front. Oncol."},{"key":"prgbaea045bib3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100396","type":"journal-article","article-title":"Outcome for children with metastatic solid tumors over the last four decades","volume":"9","author":"Perkins","year":"2014","journal-title":"PLoS One"},{"key":"prgbaea045bib4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/ije\/dyaa176","type":"journal-article","article-title":"Trends in paediatric central nervous system tumour incidence by global region from 1988 to 2012","volume":"50","author":"Williams","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"prgbaea045bib5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836452","type":"journal-article","article-title":"Immunotherapy associated neurotoxicity in pediatric oncology","volume":"12","author":"Shalabi","year":"2022","journal-title":"Front. Oncol."},{"key":"prgbaea045bib6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.sempedsurg.2011.10.009","type":"journal-article","article-title":"Neuroblastoma","volume":"21","author":"Davidoff","year":"2012","journal-title":"Semin. Pediatr. Surg."},{"key":"prgbaea045bib7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jpedsurg.2018.09.004","type":"journal-article","article-title":"Update on neuroblastoma","volume":"54","author":"Newman","year":"2019","journal-title":"J. Pediatr. Surg."},{"key":"prgbaea045bib8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31317","type":"journal-article","article-title":"Modern surgical strategies in pediatric neuroblastoma: evolving approaches and treatment principles","volume":"72 Suppl 2","author":"Williams","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"prgbaea045bib9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1634\/theoncologist.2019-0615","type":"journal-article","article-title":"A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies","volume":"25","author":"Cohen","year":"2020","journal-title":"Oncologist"},{"key":"prgbaea045bib10","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.jpedsurg.2023.07.001","type":"journal-article","article-title":"Implications of immunotherapy for pediatric malignancies: a summary from the APSA cancer committee","volume":"58","author":"Talbot","year":"2023","journal-title":"J. Pediatr. Surg."},{"key":"prgbaea045bib11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","type":"journal-article","article-title":"Pediatric cancer immunotherapy: opportunities and challenges","volume":"20","author":"Wedekind","year":"2018","journal-title":"Paediatr. Drugs"},{"key":"prgbaea045bib12","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3390\/cancers14092314","type":"journal-article","article-title":"CXCR4\/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy","volume":"14","author":"Mezzapelle","year":"2022","journal-title":"Cancers"},{"key":"prgbaea045bib13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1467602","type":"journal-article","article-title":"Targeting extracellular matrix stiffness for cancer therapy","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Immunol."},{"key":"prgbaea045bib14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00262-024-03675-9","type":"journal-article","article-title":"Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion","volume":"73","author":"Yu","year":"2024","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"prgbaea045bib15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","type":"journal-article","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"prgbaea045bib16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noy084","type":"journal-article","article-title":"Immunotherapy in CNS cancers: the role of immune cell trafficking","volume":"21","author":"Ratnam","year":"2019","journal-title":"Neuro Oncol."},{"key":"prgbaea045bib17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10555-024-10208-4","type":"journal-article","article-title":"CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials","volume":"43","author":"Ronsley","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"prgbaea045bib18","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.3390\/cancers13184704","type":"journal-article","article-title":"Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma","volume":"13","author":"Terry","year":"2021","journal-title":"Cancers"},{"key":"prgbaea045bib19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fonc.2017.00082","type":"journal-article","article-title":"A comparison of pediatric vs. adult patients with the Ewing sarcoma family of tumors","volume":"7","author":"Verma","year":"2017","journal-title":"Front. Oncol."},{"key":"prgbaea045bib20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000533412","type":"journal-article","article-title":"Disparate outcomes, biologic and therapeutic differences in pediatric versus adult patients with Ewing sarcoma","volume":"102","author":"Wytiaz","year":"2024","journal-title":"Oncology"},{"key":"prgbaea045bib21","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S1470-2045(17)30099-2","type":"journal-article","article-title":"Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts","volume":"18","author":"van der Graaf","year":"2017","journal-title":"Lancet Oncol."},{"key":"prgbaea045bib22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","type":"journal-article","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"prgbaea045bib23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","type":"journal-article","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"prgbaea045bib24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","type":"journal-article","article-title":"An introduction to chimeric antigen receptor (CAR) T\u201a\u00c4\u00eacell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"prgbaea045bib25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","type":"journal-article","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"prgbaea045bib26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","type":"journal-article","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"prgbaea045bib27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","type":"journal-article","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"prgbaea045bib28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","type":"journal-article","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Bufalo","year":"2023","journal-title":"New Engl. J. Med."},{"key":"prgbaea045bib29","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","type":"journal-article","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"prgbaea045bib30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","type":"journal-article","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"prgbaea045bib31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10555-024-10214-6","type":"journal-article","article-title":"CAR T-cells for pediatric solid tumors: where to go from here?","volume":"43","author":"Trautmann","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"prgbaea045bib32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/EDBK_200773","type":"book","article-title":"The landscape of CAR T cells beyond acute lymphoblastic leukemia for pediatric solid tumors","author":"DeRenzo","year":"2018"},{"key":"prgbaea045bib33","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.3390\/jcm12062326","type":"journal-article","article-title":"CAR T-Cell Therapy in Children with Solid Tumors","volume":"12","author":"Kulczycka","year":"2023","journal-title":"J. Clin. Med."},{"key":"prgbaea045bib34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100870","type":"journal-article","article-title":"Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia"},{"key":"prgbaea045bib35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","type":"journal-article","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"prgbaea045bib36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","type":"journal-article","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"prgbaea045bib37","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","type":"journal-article","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"prgbaea045bib38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","type":"journal-article","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol."},{"key":"prgbaea045bib39","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200980","type":"journal-article","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"prgbaea045bib40","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","type":"journal-article","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"prgbaea045bib41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","type":"journal-article","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl. J. Med."},{"key":"prgbaea045bib42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","type":"journal-article","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"key":"prgbaea045bib43","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10555-024-10212-8","type":"journal-article","article-title":"Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives","volume":"43","author":"Rados","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"prgbaea045bib44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-025-04010-6","type":"journal-article","article-title":"GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout","volume":"74","author":"J\u221a\u00b0nemann","year":"2025","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"prgbaea045bib45","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","type":"journal-article","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"prgbaea045bib46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","type":"journal-article","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"prgbaea045bib47","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221094244","type":"journal-article","article-title":"Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transplant."},{"key":"prgbaea045bib48","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/ph17080991","type":"journal-article","article-title":"Immune checkpoint inhibitors for pediatric cancers: is it still a stalemate?","volume":"17","author":"Jaing","year":"2024","journal-title":"Pharmaceuticals"},{"key":"prgbaea045bib49","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/ijms25063225","type":"journal-article","article-title":"Pediatric solid cancers: dissecting the tumor microenvironment to improve the results of clinical immunotherapy","volume":"25","author":"Belgiovine","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"prgbaea045bib50","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/cancers13102374","type":"journal-article","article-title":"Pediatric tumors-mediated inhibitory effect on NK Cells: the case of neuroblastoma and wilms\u2019 tumors","volume":"13","author":"Pelosi","year":"2021","journal-title":"Cancers"},{"key":"prgbaea045bib51","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/cells12060885","type":"journal-article","article-title":"Monocyte and macrophage in neuroblastoma: blocking their pro-tumoral functions and strengthening their crosstalk with natural killer cells","volume":"12","author":"Vitale","year":"2023","journal-title":"Cells"},{"key":"prgbaea045bib52","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/0008-5472.CAN-21-0691","type":"journal-article","article-title":"Neuroblastoma formation requires unconventional CD4 T cells and arginase-1-dependent myeloid cells","volume":"81","author":"Van de Velde","year":"2021","journal-title":"Cancer Res."},{"key":"prgbaea045bib53","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1593\/neo.04316","type":"journal-article","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"prgbaea045bib54","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1812535","type":"journal-article","article-title":"Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma","volume":"2018","author":"Vanichapol","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"prgbaea045bib55","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","type":"journal-article","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"prgbaea045bib56","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.7150\/thno.92481","type":"journal-article","article-title":"A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18\/CHO","volume":"14","author":"Trautwein","year":"2024","journal-title":"Theranostics"},{"key":"prgbaea045bib57","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/cancers14246051","type":"journal-article","article-title":"GD2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: a matter of subtype","volume":"14","author":"Paret","year":"2022","journal-title":"Cancers"},{"key":"prgbaea045bib58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-025-00784-0","type":"journal-article","article-title":"The progress and prospects of targeting the adenosine pathway in cancer immunotherapy","volume":"13","author":"Yang","year":"2025","journal-title":"Biomark. Res."},{"key":"prgbaea045bib59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115708","type":"journal-article","article-title":"The immune landscape of pediatric (extra) cranial solid tumors: a systematic review and integration of immunohistochemistry and single-cell RNA sequencing data","volume":"228","author":"Bergsma","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"prgbaea045bib60","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1182\/blood-2022-158029","type":"journal-article","article-title":"Safety and activity of flotetuzumab in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia: results from the COG PEPN1812 Phase 1 Trial","volume":"140","author":"Lamble","year":"2022","journal-title":"Blood"},{"key":"prgbaea045bib61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","type":"journal-article","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-stevaux","year":"2024","journal-title":"Front. Immunol."},{"key":"prgbaea045bib62","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","type":"journal-article","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"prgbaea045bib63","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","type":"journal-article","article-title":"A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function","volume":"11","author":"Lange","year":"2021","journal-title":"Cancer Discov."},{"key":"prgbaea045bib64","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","type":"journal-article","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"New Engl. J. Med."},{"key":"prgbaea045bib65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","type":"journal-article","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"prgbaea045bib66","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13534-025-00499-z","type":"journal-article","article-title":"Nanoengineered cytotoxic T cells for photoacoustic image-guided combinatorial cancer therapy","volume":"15","author":"Lee","year":"2025","journal-title":"Biomed. Eng. Lett."},{"key":"prgbaea045bib67","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1039\/D4BM01677G","type":"journal-article","article-title":"Recent advances in non-invasive in vivo tracking of cell-based cancer immunotherapies","volume":"13","author":"Kulkarni","year":"2025","journal-title":"Biomater. Sci."},{"key":"prgbaea045bib68","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1021\/acsnano.4c12929","type":"journal-article","article-title":"In Vivo ultrasound and photoacoustic imaging of nanoparticle-engineered T cells and post-treatment assessment to guide adoptive cell immunotherapy","volume":"19","author":"Kubelick","year":"2025","journal-title":"ACS Nano"},{"key":"prgbaea045bib69","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.2967\/jnumed.118.208041","type":"journal-article","article-title":"Antibody with infinite affinity for In Vivo tracking of genetically engineered lymphocytes","volume":"59","author":"Krebs","year":"2018","journal-title":"J. Nucl. Med."},{"key":"prgbaea045bib70","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2967\/jnumed.124.267876","type":"journal-article","article-title":"In Vivo PET imaging of 89Zr-Labeled natural killer cells and the modulating effects of a therapeutic antibody","volume":"65","author":"Pham","year":"2024","journal-title":"J. Nucl. Med."},{"key":"prgbaea045bib71","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jacr.2018.04.011","type":"journal-article","article-title":"Ionizing radiation use and cancer predisposition syndromes in children","volume":"15","author":"Reid","year":"2018","journal-title":"J. Am. Coll. Radiol."},{"key":"prgbaea045bib72","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-25-0597","type":"journal-article","article-title":"Radiation concepts and considerations for pediatric cancer predisposition syndrome surveillance: a report from the 2023 AACR childhood cancer predisposition workshop","volume":"31","author":"Voss","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"prgbaea045bib73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102363119","type":"journal-article","article-title":"In vivo imaging of nanoparticle-labeled CAR T cells","volume":"119","author":"Kiru","year":"2022","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"prgbaea045bib74","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","type":"journal-article","article-title":"68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial","volume":"15","author":"Shen","year":"2024","journal-title":"Nat. Commun."},{"key":"prgbaea045bib75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12967-025-07419-w","type":"journal-article","article-title":"The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy","volume":"24","author":"Tong","year":"2025","journal-title":"J. Transl. Med."},{"key":"prgbaea045bib76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202515111","type":"journal-article","article-title":"Protease-activated plasmonic nanosensors for predictive ultrasound-guided photoacoustic imaging of tumor responses to adoptive T cell therapy","volume":"13","author":"Kim","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Progress in Biomedical Engineering"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:38:38Z","timestamp":1789115918000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/aea045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,12,1]]}},"URL":"https:\/\/doi.org\/10.1088\/2516-1091\/aea045","relation":{},"ISSN":["2516-1091"],"issn-type":[{"value":"2516-1091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach","name":"article_title","label":"Article Title"},{"value":"Progress in Biomedical Engineering","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2026 The Author(s). Published by IOP Publishing Ltd","name":"copyright_information","label":"Copyright Information"},{"value":"2026-03-01","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-08-28","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-09-11","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}